Another pretty harmful potential downside of "right to try" is that while FDA may no longer hold as much sway, payers will still be gatekeepers. Payers will de

Another pretty harmful potential downside of "right to try" is that while FDA may no longer hold as much sway, payers will still be gatekeepers. Payers will decide what to pay based on evidence and will not pay for drugs with little evidence to support their effectiveness. So patients will be stuck with the costs, and end up paying more than they do now There is precedent for this in the world of molecular diagnostics. Certain tests can be marketed without FDA approval. However few companies are successful because insurers wont pay and patients wont pay enough